ONC-783 / OncoC4 - LARVOL DELTA

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: OncoC4, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Breast Cancer • Colorectal Cancer • Oncology • Ovarian Cancer • Solid Tumor

OncoC4…announced dosing of the first patient following the clearance of the Investigational New Drug (IND) application for a Phase 1 clinical trial (NCT07408258) of ONC-783, the company's investigational T-cell engager developed based on the proprietary neoCD24 platform (PRNewswire) - "ONC-783 is being tested in ONC-783-001, a Phase 1 trial in the US for patients with advanced solid tumors. The first study patient was successfully dosed at Columbia University Irving Medical Center. The treatment was well tolerated. No severe Adverse Events, Cytokine Release Syndrome, or Immune Effector Cell-Associated Neurotoxicity Syndrome have been observed to date."

Trial status • Solid Tumor

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: OncoC4, Inc.

First-in-human • New P1 trial • Breast Cancer • Colorectal Cancer • Ovarian Cancer • Solid Tumor

Legacy OncoC4 Wholly Owned Programs (GlobeNewswire) - "ONC-782 – CAR-T cell therapy for solid and hematological malignancies: Initiation of Phase 1 Investigator Initiated Trial in China expected in 2H 2024. ONC-783 – Bispecific mAb for hematological malignancies: IND enabling studies initiated in Q2 2024. ONC-784 – ADC for solid tumors: IND enabling studies to be initiated in Q1 2025."

New P1 trial • Preclinical • Hematological Malignancies • Oncology • Solid Tumor